Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial.

Journal of viral hepatitis - 1 Feb 2016

Stahmeyer J T, Krauth C, Bert F, Pfeiffer-Vornkahl H, Alshuth U, Hüppe D, Mauss S, Rossol S

Abstract excerpt

Viral hepatitis is a major public health problem affecting millions of people worldwide. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. The aim of the study was to assess outcomes and costs of treating patients with chronic hepatitis C in clinical practice in Germany. We carried out a prospective noninterventional study. Information on treatment outcomes, resource...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germany

Share to Health Care Costs

Share to Interferon-alpha

Share to Polyethylene Glycols

Share to Quality of Life

Share to Ribavirin

Source

Identifiers

PMID: 26411532
DOI: 10.1111/jvh.12471

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Costs and outcomes of treating chronic hepatitis C patients in routine care - results from a nationwide multicenter trial.PMID 26411532Read ↗

Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection.Semantic proximity Read ↗

[Cost-effectiveness of chronic hepatitis C treatment in Spain].Semantic proximity Read ↗

Medical resource utilization and costs among Australian patients with genotype 1 chronic hepatitis C: results of a retrospective observational study.Semantic proximity Read ↗

Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study.Semantic proximity Read ↗

Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.Semantic proximity Read ↗

Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options.Semantic proximity Read ↗

Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).Semantic proximity Read ↗

Clinical characteristics, healthcare costs, and resource utilization in hepatitis C vary by genotype.Semantic proximity Read ↗

Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation.Semantic proximity Read ↗

Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.Semantic proximity Read ↗

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.Semantic proximity Read ↗

What is (cost) effective in patients with chronic hepatitis C virus infection?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.